Lack of preexisting virus - neutralizing antibodies in the human population suggests that these novel
adenoviral recombinants may provide improved vaccine carriers for use in humans.
This research, funded by NIH, aims to test
adenoviral recombinants based on simian serotypes for induction of immune responses to gag / pol / rev of HIV - 1 or SIV - 1 in a mouse model.
In animal models, E1 - deleted human
adenoviral recombinants of the serotype 5 (AdHu5) have shown high efficacy as vaccine carriers.
Not exact matches
To circumvent this problem, novel replication - defective
adenoviral vaccine carriers based on El - deleted
recombinants of chimpanzee - derived adenoviruses were developed.